Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir_老虎社区_美港股上老虎

Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir

T-Reuters2021-07-17

Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

170

EHG
·2021-07-19
Like
回复
点赞
举报
7a1f5064
·2021-07-18
Hello
回复
2
举报
CPKoh
·2021-07-18
Great
回复
2
举报
Kukudosmin
·2021-07-18
Ok
回复
1
举报
Ei_888
·2021-07-18
Ok
回复
1
举报
Tomcatanty
·2021-07-18
Wow
回复
4
举报
收起
- Ei_888:
  👌
  2021-07-18
  回复
  举报
- sh99:
  harishan
  2021-07-18
  回复
  举报
Summerlim
·2021-07-18
Good
回复
3
举报
Jfm9513
·2021-07-18
good
回复
4
举报
收起
- Benstonk:
  Nice
  2021-07-18
  回复
  举报
TinyRabbit
·2021-07-18
Boom
回复
5
举报
收起
- Tan123:
  headshot
  2021-07-18
  回复
  举报
KFChen
·2021-07-18
Wow
回复
3
举报
WarisHeng
·2021-07-18
Good
回复
3
举报
收起
- WarisHeng:
  Good
  2021-07-18
  回复
  举报
Jackytan
·2021-07-18
Nice
回复
1
举报
SeanSak
·2021-07-18
Like n comment
回复
3
举报
收起
- Bin8:
  yes
  2021-07-18
  回复
  举报
sfleong1
·2021-07-18
Like n comment
回复
3
举报
收起
- Zhengxiang:
  [Great]
  2021-07-18
  回复
  举报
Jazling
·2021-07-18
Wow
回复
3
举报
收起
- Jazling:
  Ok
  2021-07-18
  回复
  举报
SPOT_ON
·2021-07-18
Like n follow
回复
3
举报
Ming83
·2021-07-18
Hi
回复
3
举报
james_l
·2021-07-18
Nice
回复
4
举报
收起
- Ming83:
  Hi
  2021-07-18
  回复
  举报
AccX
·2021-07-18
Great
回复
4
举报
LaughingGold
·2021-07-18
Time to moon
回复
4
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2152894306?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-17 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2152894306","market":"us","top_or_hot":-1,"title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","media":"T-Reuters","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n2021-07-17 18:22 北京时间&nbsp;&nbsp;&nbsp;<strong>T-Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was...</p>\n\n<a href=\"None\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LHDX","symbol_name":"Lucira Health, Inc.","start_time":0,"source_url":null,"article_id":"2152894306","we_media_id":"1086160438","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","pubTimestamp":1626517346,"sourceInfo":null,"weMediaInfo":{"media_name":"T-Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LHDX":"Lucira Health, Inc.","LABP":"Landos Biopharma, Inc.","GILD":"吉利德科学","APR":"Apria, Inc.","SANA":"Sana Biotechnology, Inc.","CGEM":"Cullinan Therapeutics"},"translate_title":"Gilead说3期数据支持Lenacapavir的持续长效疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APR":0.9,"CGEM":0.9,"GILD":0.9,"LABP":0.9,"LHDX":0.9,"SANA":0.9},"content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":173172925,"gmtCreate":1626650651267,"gmtModify":1633925344242,"author":{"id":"3586941861951066","authorId":"3586941861951066","name":"EHG","avatar":"https://static.tigerbbs.com/28e4734e50f795c3218330cbb6c3e9a0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586941861951066","authorIdStr":"3586941861951066"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173172925","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173358549,"gmtCreate":1626620932581,"gmtModify":1633925450318,"author":{"id":"4089720653683940","authorId":"4089720653683940","name":"7a1f5064","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089720653683940","authorIdStr":"4089720653683940"},"htmlText":"Hello","listText":"Hello","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173358549","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173336399,"gmtCreate":1626614396911,"gmtModify":1633925490389,"author":{"id":"3561517799283339","authorId":"3561517799283339","name":"CPKoh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3561517799283339","authorIdStr":"3561517799283339"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173336399","repostId":2152894306,"repostType":2,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173339540,"gmtCreate":1626614006480,"gmtModify":1633925493968,"author":{"id":"4087297462574060","authorId":"4087297462574060","name":"Kukudosmin","avatar":"https://static.tigerbbs.com/fe82a55d4d107e643c3d79336bd97bb3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087297462574060","authorIdStr":"4087297462574060"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173339540","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":173004582,"gmtCreate":1626582475346,"gmtModify":1633925678597,"author":{"id":"3585533261543358","authorId":"3585533261543358","name":"Ei_888","avatar":"https://static.tigerbbs.com/117fa34406876f996514937472ec57e6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585533261543358","authorIdStr":"3585533261543358"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173004582","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179748031,"gmtCreate":1626580777523,"gmtModify":1633925700336,"author":{"id":"4088424873177630","authorId":"4088424873177630","name":"Tomcatanty","avatar":"https://static.tigerbbs.com/815fae20f153a61faa55342edbb559b3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088424873177630","authorIdStr":"4088424873177630"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/179748031","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5252811,"gmtCreate":1626582470075,"gmtModify":1635226823577,"authorId":3585533261543358,"author":{"id":3585533261543358,"idStr":"3585533261543358","authorId":3585533261543358,"name":"Ei_888","avatar":"https://static.tigerbbs.com/117fa34406876f996514937472ec57e6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179748031,"type":1,"supId":0,"prevId":0,"content":"👌","text":"👌","html":"👌"},{"id":5254174,"gmtCreate":1626602665222,"gmtModify":1635226703204,"authorId":3582013951378523,"author":{"id":3582013951378523,"idStr":"3582013951378523","authorId":3582013951378523,"name":"sh99","avatar":"https://static.tigerbbs.com/95985dfcd15851145b63b9903fdb5bfc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179748031,"type":1,"supId":0,"prevId":0,"content":"harishan","text":"harishan","html":"harishan"}],"langContent":"EN"},{"id":179423418,"gmtCreate":1626572735734,"gmtModify":1633925814046,"author":{"id":"3581752680600976","authorId":"3581752680600976","name":"Summerlim","avatar":"https://static.tigerbbs.com/386db569a872d30f99d887216f7ca0dd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581752680600976","authorIdStr":"3581752680600976"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179423418","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179414168,"gmtCreate":1626571268054,"gmtModify":1633925836259,"author":{"id":"3567897607865279","authorId":"3567897607865279","name":"Jfm9513","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3567897607865279","authorIdStr":"3567897607865279"},"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179414168","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5253634,"gmtCreate":1626592709858,"gmtModify":1635226748748,"authorId":3574851080358491,"author":{"id":3574851080358491,"idStr":"3574851080358491","authorId":3574851080358491,"name":"Benstonk","avatar":"https://static.tigerbbs.com/c8a964cfa9223e4704989c9a4b9b772e","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179414168,"type":1,"supId":0,"prevId":0,"content":" Nice","text":" Nice","html":" Nice"}],"langContent":"EN"},{"id":179545393,"gmtCreate":1626567933912,"gmtModify":1633925885380,"author":{"id":"3586854302245038","authorId":"3586854302245038","name":"TinyRabbit","avatar":"https://static.tigerbbs.com/6685482ed446811291c305271d57d5ed","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586854302245038","authorIdStr":"3586854302245038"},"htmlText":"Boom","listText":"Boom","text":"Boom","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179545393","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5250992,"gmtCreate":1626570011967,"gmtModify":1635226990125,"authorId":3575263084566569,"author":{"id":3575263084566569,"idStr":"3575263084566569","authorId":3575263084566569,"name":"Tan123","avatar":"https://static.tigerbbs.com/f62a61b3de783a68b73436f05185453a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179545393,"type":1,"supId":0,"prevId":0,"content":"<u>headshot</u>","text":"<u>headshot</u>","html":"<u>headshot</u>"}],"langContent":"EN"},{"id":179556360,"gmtCreate":1626567119850,"gmtModify":1633925896687,"author":{"id":"3576990193651421","authorId":"3576990193651421","name":"KFChen","avatar":"https://static.tigerbbs.com/6830fa3fe8a82d29953fbb2e6153801e","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3576990193651421","authorIdStr":"3576990193651421"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179556360","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179558122,"gmtCreate":1626567061766,"gmtModify":1633925897631,"author":{"id":"4089459519603980","authorId":"4089459519603980","name":"WarisHeng","avatar":"https://static.tigerbbs.com/f152c428f94eef79d97567fa3c7400da","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089459519603980","authorIdStr":"4089459519603980"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179558122","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5250610,"gmtCreate":1626567076842,"gmtModify":1635227024178,"authorId":4089459519603980,"author":{"id":4089459519603980,"idStr":"4089459519603980","authorId":4089459519603980,"name":"WarisHeng","avatar":"https://static.tigerbbs.com/f152c428f94eef79d97567fa3c7400da","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179558122,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":179522382,"gmtCreate":1626566277946,"gmtModify":1631893871354,"author":{"id":"3555065151273039","authorId":"3555065151273039","name":"Jackytan","avatar":"https://static.tigerbbs.com/619b88f86d5ffa77c2e81644af36a492","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3555065151273039","authorIdStr":"3555065151273039"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179522382","repostId":2152894306,"repostType":2,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179567735,"gmtCreate":1626565767727,"gmtModify":1633925911198,"author":{"id":"3581585664475701","authorId":"3581585664475701","name":"SeanSak","avatar":"https://static.tigerbbs.com/4a62d3d455150e01d4dc6c67bd4f9c0d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581585664475701","authorIdStr":"3581585664475701"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179567735","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5250463,"gmtCreate":1626565928859,"gmtModify":1635227037292,"authorId":3581566554984741,"author":{"id":3581566554984741,"idStr":"3581566554984741","authorId":3581566554984741,"name":"Bin8","avatar":"https://static.tigerbbs.com/d4547f1e0822b414bcadb0942d311dbc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179567735,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"},{"id":179561946,"gmtCreate":1626565059385,"gmtModify":1633925918258,"author":{"id":"3583570345500843","authorId":"3583570345500843","name":"sfleong1","avatar":"https://static.tigerbbs.com/2ec42f3f2b911279950a45a9140bc358","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3583570345500843","authorIdStr":"3583570345500843"},"htmlText":"Like n comment","listText":"Like n comment","text":"Like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179561946","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5250416,"gmtCreate":1626565561479,"gmtModify":1635227041691,"authorId":3581662739379335,"author":{"id":3581662739379335,"idStr":"3581662739379335","authorId":3581662739379335,"name":"Zhengxiang","avatar":"https://static.tigerbbs.com/90952562f226a13c89669afb4338a801","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179561946,"type":1,"supId":0,"prevId":0,"content":"[Great]","text":"[Great]","html":"[Great]"}],"langContent":"EN"},{"id":179587653,"gmtCreate":1626564755172,"gmtModify":1633925921254,"author":{"id":"3566821013640470","authorId":"3566821013640470","name":"Jazling","avatar":"https://static.tigerbbs.com/85e0a83573d9307f57fca9b2baed72af","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3566821013640470","authorIdStr":"3566821013640470"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179587653","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5250313,"gmtCreate":1626564766927,"gmtModify":1635227050925,"authorId":3566821013640470,"author":{"id":3566821013640470,"idStr":"3566821013640470","authorId":3566821013640470,"name":"Jazling","avatar":"https://static.tigerbbs.com/85e0a83573d9307f57fca9b2baed72af","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179587653,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":179580608,"gmtCreate":1626563633304,"gmtModify":1633925929995,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Like n follow&nbsp;","listText":"Like n follow&nbsp;","text":"Like n follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179580608","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179535837,"gmtCreate":1626561573329,"gmtModify":1633925941013,"author":{"id":"3566819412630327","authorId":"3566819412630327","name":"Ming83","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3566819412630327","authorIdStr":"3566819412630327"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179535837","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179539118,"gmtCreate":1626560140534,"gmtModify":1633925945967,"author":{"id":"3563436875655076","authorId":"3563436875655076","name":"james_l","avatar":"https://static.tigerbbs.com/7960ea5c640db331ff2de0da32f6a611","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3563436875655076","authorIdStr":"3563436875655076"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/179539118","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5250079,"gmtCreate":1626561583105,"gmtModify":1635227071703,"authorId":3566819412630327,"author":{"id":3566819412630327,"idStr":"3566819412630327","authorId":3566819412630327,"name":"Ming83","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":179539118,"type":1,"supId":0,"prevId":0,"content":"Hi","text":"Hi","html":"Hi"}],"langContent":"EN"},{"id":179509604,"gmtCreate":1626547021108,"gmtModify":1633925961810,"author":{"id":"3581947268158712","authorId":"3581947268158712","name":"AccX","avatar":"https://static.tigerbbs.com/91b8ed5a1ff8ca5a0ff1e655c6ed4c59","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581947268158712","authorIdStr":"3581947268158712"},"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179509604","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":179509148,"gmtCreate":1626546808184,"gmtModify":1631885481292,"author":{"id":"3578315347178182","authorId":"3578315347178182","name":"LaughingGold","avatar":"https://static.tigerbbs.com/c63e9f2fcbdcd3959a91e670e58b0d1d","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3578315347178182","authorIdStr":"3578315347178182"},"htmlText":"Time to moon","listText":"Time to moon","text":"Time to moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/179509148","repostId":2152894306,"repostType":4,"repost":{"id":"2152894306","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1626517346,"share":"https://www.laohu8.com/m/news/2152894306?lang=&edition=full","pubTime":"2021-07-17 18:22","market":"hk","language":"en","title":"Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir","url":"https://stock-news.laohu8.com/highlight/detail?id=2152894306","media":"T-Reuters","summary":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy O","content":"<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead Says Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-07-17 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SANA":"Sana Biotechnology, Inc.","LABP":"Landos Biopharma, Inc.","LHDX":"Lucira Health, Inc.","GILD":"吉利德科学","CGEM":"Cullinan Therapeutics","APR":"Apria, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152894306","content_text":"Gilead Sciences Inc:Gilead Sciences Inc - New Phase 3 Data Support Sustained, Long-Acting Efficacy Of Lenacapavir, Gilead'S Investigational Hiv-1 Capsid Inhibitor.Gilead Sciences Inc - Lenacapavir Was Generally Well Tolerated, With No Adverse Events.Gilead Sciences Inc - Week 26 Data From Capella Trial Show Lenacapavir Leads To High Rates Of Virologic Suppression.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":170,"commentSize":25,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}